RXI Pharma (RXII) Reports In-Line Q3 EPS

RXI Pharma (NASDAQ: RXII) reported Q3 EPS of ($0.04), in-line with the analyst estimate of ($0.04).

At September 30, 2015, the Company had cash, cash equivalents and short-term investments of approximately $12.0 million, compared with cash and cash equivalents of $8.5 million at December 31, 2014.

The Company believes that its existing cash, cash equivalents and short-term investments should be sufficient to fund operations for at least one year.

For earnings history and earnings-related data on RXI Pharma (RXII) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
• Robinhood shares climb on summit momentum and analyst support